YLS has developed the EBDLR v2.0, a portable medical device designed to support liver function and promote regeneration in patients experiencing acute liver failure, a condition with a high mortality rate and limited treatment options. This device offers a cost-effective alternative to liver transplantation, addressing the critical need for accessible and timely intervention in life-threatening liver conditions.
Funding
Funding not disclosed
Founders
Product
Problem
Acute liver failure (ALF) is a life-threatening condition characterized by rapid deterioration of liver function, resulting in a high mortality rate. Liver transplantation is often the only available treatment, but it is expensive, has limited availability due to organ shortages, and is not an option for all patients.
Solution
Ykrita Lifesciences has developed the EBDLR v2.0, a portable medical device designed to support liver function and promote liver regeneration in patients with acute liver failure. The EBDLR v2.0 aims to supplement the liver's function, enabling it to regenerate with the device's support. Pre-clinical studies have demonstrated promising results in rescuing subjects with ALF. The device offers a more accessible and cost-effective alternative to liver transplantation for patients experiencing acute liver failure.
Target Audience
The primary target audience includes patients experiencing acute liver failure, hepatologists, hospitals, and medical centers specializing in liver diseases and transplantation.
Features
- Portable and lightweight design for ease of use and transport.
- Designed to supplement liver function and promote regeneration.
- Aims to address various causes of ALF, including drug toxicity and hepatitis infections.
- Patents filed in India, PCT, and USPTO, highlighting its innovative design.